Japan's PMDA revises precautions for multiple products

被引：0

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1661卷 / 1期

关键词：

D O I：

10.1007/s40278-017-33292-3

中图分类号：

学科分类号：

摘要：

引用

页码：4 / 4

共 50 条

[31] Package insert revisions required: Japan's PMDA findings
Reactions Weekly, 2016, 1615 (1) : 4 - 4
[32] Japan's MHLW/PMDA recommends package insert revisions
Reactions Weekly, 2018, 1732 (1) : 1 - 1
[33] PMDA: precautions should be revised for Covid-19 vaccine
Reactions Weekly, 2021, 1866 (1) : 4 - 4
[34] Japan's PMDA set to launch new medical information database
Reactions Weekly, 2018, 1695 (1) : 2 - 2
[35] Japan's PMDA warns of serious AEs with pivoxil use in kids
Reactions Weekly, 2012, 1407 (1) : 2 - 2
[36] PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of atezolizumab for alveolar soft part sarcoma, epcoritamab for follicular lymphoma, and isatuximab for multiple myeloma in Japan
Noriomi Matsumura
Masaki Mandai
International Journal of Clinical Oncology, 2025, 30 (5) : 825 - 826
[37] Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022
Ryosuke Kuribayashi
Ayuki Nakano
Aya Hariu
Yasuhiro Kishioka
Futaba Honda
BioDrugs, 2023, 37 : 443 - 451
[38] The FDA revises requirements for levothyroxine products
Burman, Kenneth
Hennessey, James
McDermott, Michael
Wartofsky, Leonard
Emerson, Charles
THYROID, 2008, 18 (05) : 487 - 490
[39] Japan PMDA's Relief System for ADRs: 5-year analysis
Reactions Weekly, 2018, 1727 (1) : 2 - 2
[40] PMDA's Challenge to Accelerate Clinical Development and Review of New Drugs in Japan
Ichimaru, K.
Toyoshima, S.
Uyama, Y.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (04) : 454 - 457

← 1 2 3 4 5 →